Emese Zsiros
Roswell Park Cancer Institute
6
6
3
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Shannon N Westin
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
A P Chen
National Cancer Institute LAO
Shared therapeutic areas:
Worked with same sponsors:
Vassiliki Papadimitrakopoulou
SWOG Cancer Research Network
Shared therapeutic areas:
Worked with same sponsors:
Lei Li, M.D.
Peking Union Medical College Hospital
Shared therapeutic areas:
Aminah Jatoi, M.D.
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Carla Prado, PhD
University of Alberta
Shared therapeutic areas:
Sandro Pignata, M.D., Ph.D.
National Cancer Institute, Naples
Shared therapeutic areas:
David M Kushner, MD
University of Wisconsin, Madison
Shared therapeutic areas:
Worked with same sponsors:
Deborah E Citrin, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
David S. Miller, MD
Simmons Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
All 6 trials loaded